Table 1 Clinicopathological features of NSCLC patients in the training and validation datasets
From: CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer
Characteristics | Overall N = 127 | Training set N = 62 | Validation I set N = 18 | Validation II set N = 47 |
|---|---|---|---|---|
Gender | Â | Â | Â | Â |
 Female | 34 (27%) | 24 (39%) | 6 (33%) | 4 (8.5%) |
 Male | 79 (62%) | 24 (39%) | 12 (67%) | 43 (91%) |
 Unknow | 14 (11%) | 14 (22%) | 0 (0.0%) | 0 (0.0%) |
Clinical T stage | Â | Â | Â | Â |
 T1-T2 | 54 (43%) | 39 (63%) | 7 (39%) | 8 (17%) |
 T3-T4 | 39 (31%) | 9 (14%) | 8 (44%) | 22 (47%) |
 Unknow | 34 (27%) | 14 (23) | 3 (17%) | 17 (36%) |
Clinical N stage | Â | Â | Â | Â |
 N0-N1 | 50 (39%) | 40 (64%) | 5 (28%) | 5 (11%) |
 N2-N3 | 44 (35%) | 8 (13%) | 11 (61%) | 25 (53%) |
 Unknow | 33 (26%) | 14 (23%) | 2 (11%) | 17 (36%) |
Clinical M stage | Â | Â | Â | Â |
 M0 | 57 (45%) | 39 (63%) | 2 (11%) | 16 (34%) |
 M1 | 29 (23%) | 2 (3.0%) | 13 (72%) | 14 (30%) |
 Unknow | 41 (32%) | 21 (34%) | 3 (17%) | 17 (36%) |
Clinical TNM stage | Â | Â | Â | Â |
 Stage I-II | 33 (26%) | 31 (50%) | 0 (0.0%) | 2 (4.0%) |
 Stage III-IV | 68 (54%) | 16 (26%) | 15 (83%) | 37 (79%) |
 Unknow | 26 (20%) | 15 (24%) | 3 (17%) | 8 (17%) |
Age, median (range) | 66 (39–84) | 66 (39–84) | 64 (50–79) | 66 (54–79) |
Histology | Â | Â | Â | Â |
 LUAD | 56 (44%) | 19 (31%) | 18 (100%) | 19 (40%) |
 LUSC | 57 (45%) | 29 (47%) | 0 (0.0%) | 28 (60%) |
 Unknow | 14 (11%) | 14 (22%) | 0 (0.0%) | 0 (0.0%) |